Study of IbrutNCT03112174inib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

Official Title

Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma

Summary:

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

Trial Description

Primary Outcome:

  • Occurrence of Tumour Lysis Syndrome (TLS)
  • Occurrence of Dose Limiting Toxicities (DLT)
  • Progression-free Survival (PFS)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society